J Pharmacol Exp Ther. 2000;292:288–94. http://www.ncbi.nlm.nih.gov/pubmed/10604960. 3. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a
double-blind, randomized trial. Staurosporine concentration Circulation. 2003;107:2690–6. http://www.ncbi.nlm.nih.gov/pubmed/12742979. 4. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with JAK inhibitor worsening heart failure. JAMA. 2004;291:1963–71. 5. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005;11:260–9.PubMedCrossRef 6. Blair JEA, Pang PS, Schrier RW, selleck inhibitor et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32:2563–72. 7. Vaduganathan M, Gheorghiade M, Pang PS, et al. Efficacy of oral tolvaptan in acute heart failure
patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012;13:415–22. http://www.ncbi.nlm.nih.gov/pubmed/22673023. 8. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–8. 9. Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol. 2009;13:438–46. http://www.ncbi.nlm.nih.gov/pubmed/19452240.
10. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67–76. http://www.ncbi.nlm.nih.gov/pubmed/22120095. 11. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan Mirabegron reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2012. http://www.ncbi.nlm.nih.gov/pubmed/23159210. 12. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96. http://www.ncbi.nlm.nih.gov/pubmed/19215833. 13. Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12–9. http://www.ncbi.nlm.nih.gov/pubmed/18931492. 14.